ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Active, not recruiting · NCT02688712 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm, rectum adenocarcinoma | Active, not recruiting | Phase 2 | 2026-04-13 | NCT02688712 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Providence Health & Services | 35 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Providence Cancer Center | Portland | United States | 5 |